Assessment of risk factors for acute graft-versus-host disease (aGvHD) might help in tailoring the intensity of prophylactic immunosuppression after allogeneic stem cell transplantation (SCT), thereby decreasing the relapse rate in leukaemia patients. In this study, we analysed whether the number of recipient blood T cells and plasma levels of different cytokines were correlated with the risk of aGvHD after allogeneic SCT. Analyses were performed in 23 patients receiving pSCT immediately before or during the first 2 days of the conditioning regimen. In all, 40 or more Tc-1 cells/ll pretransplant were associated with a significantly increased risk of aGvHD (10/10 patients with GvHDXII; 4/13 patients without aGvHD with a Tc-1 number 440/ll, Po0.002, Fisher's exact test). In addition, 40 or more Th-1 cells/ll pretransplant were also associated with a significantly increased risk of aGvHD (Po0.04, Fisher's exact test). Furthermore, the number of Th-2 cells was significantly higher in patients with severe aGvHD even though the median absolute cell counts were very low. However, all other investigated parameters did not reveal predictive value. In conclusion, determination of T-1 cells prior to SCT might determine patients with high/low risk of aGvHD and could thus be used to control immunosuppression after SCT. Bone Marrow Transplantation (2005) 35, 691-697.
value Allogeneic stem cell transplantation (SCT) has improved the prognosis of patients with high risk and relapsed leukaemia or lymphoma. [1] [2] [3] In CML, for example, it represents the only curative treatment. The main mechanism is an immunological reaction referred to as graft versus leukaemia effect (GvL). 4, 5 Reduction of immunosuppression early after transplantation or even infusion of donor lymphocytes has been used to increase GvL reactivity and to reduce the risk of relapse in high-risk patients. However, the outcome for these patients might be impaired by the development of severe side effects such as infectious complications, 6 ,7 organ failure 8, 9 or acute and chronic graft-versus-host disease (GvHD). 10, 11 Therefore, GvHD risk assessment of a patient prior to SCT might be essential to determine the level of immunosuppression necessary to control GvHD, allowing at the same time the development of GvT reactivity.
Cavet et al 12 reported that patients with a certain IL-10 polymorphism are more susceptible to developing severe GvHD. Furthermore, Holler et al 13 showed that an increased IL-10 production in vitro by MNC taken from stem cell recipients prior to transplantation correlated with a reduced risk of GvHD after transplantation. Thus, IL-10 production by recipient cells might suppress the development of GvHD, probably by suppression of IFN-g production.
IFN-g seems to be an essential cytokine involved in the pathogenesis of GvHD.
14,15 IFN-g is able to upregulate the expression of HLA molecules as well as adhesion molecules and control susceptibility and immunogenicity of GvHD target cells. 16, 17 It may therefore support the homing and local activation of alloreactive cells in certain target tissues. Thus, in addition to the secretion of immunosuppressive cytokines by recipient cells, the status of IFN-g-producing CD3-positive T cells (hereafter referred to as 'T-1') prior to transplantation might also be important for induction of GvHD after transplantation. We therefore investigated whether the number of detectable T-1 cells prior to, or at the beginning, of the conditioning regimen is a risk factor of severe GvHD post transplantation. In addition, the detection of T-1 cells was correlated with an analysis of T-1 regulatory plasma cytokines.
Materials and methods

Patients
In this study, we included 23 patients, who fulfilled the following criteria:
They were treated with allogeneic peripheral SCT from related or unrelated donors at our institution between December 1999 and August 2002 They gave written informed consent to participate in this study Blood samples could be obtained for our analyses between days -8 and -6 before transplantation The patients did not receive T-cell cytotoxic antibodies prior to blood drawing Details on age, diagnosis, donor status, conditioning regimen and development of severe GvHD are given in Table 1 . All patients received a myeloablative regimen followed by allogeneic SCT. The conditioning regimen consisted of total body irradiation (12 Gy) in combination with chemotherapy in 19 patients, while four patients received only chemotherapy. Prior to the conditioning regimen, patients received i.v. chemotherapy for AML (n ¼ 6), ALL (n ¼ 6), MDS (n ¼ 2) or breast cancer (n ¼ 1) according to current study protocols. Four patients with CML and one patient with MDS were pretreated with Imatinib and IFN-based regimens, three patients (MDS ¼ 2; CML ¼ 1) received only supportive treatment (Table 1) .
Materials
For cytometric analysis, monoclonal antibodies for CD3 (clone UCHT1), CD8 (clone B9.11), CD4 (clone 13B8.2), 
Flow cytometry of surface antigens
Stained cells were analysed by flow cytometry after 10 min incubation and erythrocyte lysis with OptiLyse C (Beckman Coulter, Krefeld, Germany) according to the manufacturer's protocol.
Detection of cytoplasmic cytokine
PBMNC were isolated by Ficoll density centrifugation, as previously described. 18 Cells at a density of 1 million/ml were stimulated with PMA (20 ng/ml) and ionomycin (1 mg/ ml) for 4 h in the presence of monensin (2 mM). Cells were then harvested and washed with PBS. Then, cells were stained for cell surface expression of CD3, CD4, CD8, CD14 and CD56 with specific monoclonal antibodies. Fixation and permeabilisation was carried out with Fix&Perm solution according to the manufacturer's protocol. Cytoplasmic staining of IL-4 and IFN-g was performed with specific monoclonal antibodies for 30 min at 41C in the dark. Cells were washed and analysed using of an EPICS XL cytometer (Beckman Coulter) and EXPO32 software as previously described. 18 Samples stained with matched isotype antibodies were run as controls.
Calculation of absolute cell counts
The following definition was used for T-cell subpopulations:
The absolute cell count of the T-cell subpopulations was calculated in the following way:
A ¼ (peripheral blood leucocyte count)*(% CD3 þ cells from cytometric analysis of peripheral blood cells)
Absolute cell count Th-1 or Th-2 per ml peripheral
The Tc-1 or Tc-2 subpopulations were calculated in the same way.
Detection of plasma cytokines
Plasma samples were obtained by centrifugation of whole blood and stored at -801C until determination of cytokine content by specific commercially available ELISA. In detail, samples were studied for IP-10, IL-12, MIG (all R&D systems Minneapolis, MN, USA), IL-4, IL-10, MCP-1 and TRAIL (all BD Pharmingen, San Diego, CA, USA) according to the manufacturer's protocols.
Statistics
Statistical analysis was performed using the software SPSS for Windows, version 11.0 (SPPS, Chicago, IL, USA). Differences between study groups were analysed by MannWhitney U-test or Fisher's exact test.
Results
Clinical parameters
Neither conditioning regimen (with/without TBI) nor stem cell source (RD vs URD) significantly influenced the development of severe acute GvHD (aGvHD) (XII) after transplantation in this cohort of patients. Seven out of 19 patients who received TBI for conditioning developed aGvHD XII, whereas 3/4 patients without TBI had higher grade aGvHD (ns). Four out of eight patients transplanted from a related donor and 6/15 patients transplanted from unrelated donors developed severe aGvHD (ns). In addition, no significant influence of prior treatment with/ without chemotherapy on the development of GvHD could be observed in our patient cohort. Five out of 15 patients who received intensive chemotherapy as prior treatment developed severe aGvHD, whereas 5/8 patients without intensive chemotherapy as prior treatment had higher grade GvHD (ns).
Cellular components
We found significantly increased numbers of
À IFN-g-producing cytotoxic T cells (Tc-1 cells) in the peripheral blood of patients who developed a GvHD XII after transplantation (Po0.01, Mann-Whitney U-test; median/range of patients without severe GvHD: 27.15/0-85 cells/ml (range); patients with severe GvHD: 79.15/40-197 cells/ml). In total, 40 or more Tc-1 cells/ml peripheral blood were detectable in 10/10 patients who developed GvHD XII, but only in 4/13 patients with GvHD 0 or I (Po0.002, Fisher's exact test, Figure 1a ). Furthermore, a significant difference was observed for IFN-g-producing CD3 þ CD4 þ CD14 À (Th-1) cells (Po0,05, Mann-Whitney U-test; median/range of patients without severe GvHD: 8.2/0-123.5 cells/ml (range); patients with severe GvHD: 67.1/9.1-186.7 cells/ml, Figure 1b) . A total of 40 or more Th-1 cells/ml peripheral blood were detectable in 8/10 patients who developed GvHD XII, but only in 4/13 patients with GvHD 0 or I (Po0.04, Fisher's exact test).
Even though the median age in the group of patients who developed higher grade GvHD is higher (40.5 vs 35 years), the age distribution is similar. In addition, no significant correlation between age or treatment prior to conditioning for allogeneic SCT and the number of detectable T1 cells was observed. Furthermore, no difference according to the use of ATG throughout conditioning and the development of higher grade GvHD was detectable. Notably, all six patients developing higher grade GvHD after receiving ATG throughout conditioning had high detectable Tc-1 cell numbers prior to conditioning.
In contrast, no significant differences for IL-4-producing CD3 þ CD8 þ CD56 À (Tc-2) cells were observed in patients with GvHD XII compared to those without ( Figure 1a) . The number of IL-4-producing CD3 þ CD4 þ CD14 À (Th-2) cells was significantly higher in patients who presented with severe aGvHD (Po0,05, Mann-Whitney U-test, Figure 1b) . However, the median absolute cell counts were about 17 times lower than those for Th-1 cells (median/ range in patients without severe GvHD: 0.53/0-4.5 cells/ml and in patients with severe GvHD: 3.4/0-14.5 cells/ml).
Plasma cytokines
Next, we investigated whether soluble cytokines, which are involved in the regulation of T-1 cell activation, might be increased in patients who develop severe GvHD after transplantation.
No correlation between IL-12, a potent stimulator of T-1 activation, and Tc-1 numbers was found (Spearman-Rho correlation: 0.17). In addition, IL-12 plasma concentrations were not significantly increased in patients who developed severe GvHD (Table 2) . Furthermore, levels of cytokines induced by IL-12 such as MIG, MCP-1 and IP-10 were not increased in patients who developed severe in comparison to patients without severe GvHD after transplantation even though all three chemokines could be detected in most of the samples (Table 2) . Similarly, we found no increase of IFN-g-suppressing cytokines IL-10 and IL-4 in patients without severe GvHD (Table 2) . Finally, cytokines, which might indicate tissue damage such as TRAIL, were not enhanced in patients with subsequent severe GvHD ( Table 2) .
Discussion
Several risk factors for the development of severe GvHD such as degree of HLA-matching, age or gender have been identified. [19] [20] [21] However, depending on patient cohort or transplant modalities (e.g. stem cell source, donor, conditioning regime or GvHD prophylaxis), the predictive value of these factors varied. Goker et al 22 found that HLAidentical unrelated donors, miH mismatch in HLA-identical sibling transplantation, conditioning, microenvironment, Blood for the analysis of Th-1/Th-2 cells was taken from the patients between day -8 and -6 prior to SCT. Of 23 patients, 10 developed severe GvHD after allogeneic GvHD. The number of detectable cells is depicted on the y-axis, a black bar represents the median. Spots on the baseline represent the number of patients without detectable cells of the current subset. Numbers of Th-1 cells/ml peripheral blood as well as numbers of Th-2 cells/ml peripheral blood were significantly increased in patients with severe aGvHD (Po0.05, Mann-Whitney U-test for each subset).
Table 2
Plasma cytokine levels Cytokine 0 or I GvHD XII GvHD (range (pg/ml); median (pg/ml)) (range (pg/ml); median (pg/ml)) Prognostic value of T-1 cells prior to allogeneic SCT U Banning et al age, gender and cell source are the main risk factors for the development of aGvHD. Recently, Banna et al 23 reviewed the incidence of aGvHD II-IV in 1400 reported patients. The median incidence of GvHD II-IV in the UDT patients of all considered studies was 50% with a range between 0 and 71%. Thus, the rate of patients with UDT and GvHD in our study (40%) is within this range, but slightly below the reported median incidence. Since Morishima et al 24 found that only the HLA-matching was a significant risk factor, the relatively low incidence of GvHD II-IV in our patients with UDT might be explained by the HLA typing. In our cohort, in all patients/donors, a genomic class II typing was performed. Only one patient who received URT and developed severe GvHD had a DQB1 mismatch. All other patients/donors were matched for DRB1 and DQB1. In addition, 5/14 patients with UDT were matched for HLA-A and HLA-B. The excellent matching in our cohort of patients might explain the lower incidence of GvHD in the group of unrelated transplants.
IL
Therefore, in future, other factors independent from HLA matching might become more important for predicting a severe GvHD. In our study, the number of T1 cells detectable in the patients' peripheral blood before conditioning was significantly correlated with the occurrence of aGvHDXII.
Until today the role of the immunereactive recipient cells has only rarely been evaluated. Holler et al 13 recently showed that endogenous IL-10 production by recipient MNC correlated with the risk for the development of GvHD. Patients with high spontaneous IL-10 production seem to be protected against severe GvHD. This finding seems in part to be dependent on the IL-10 genotype of the patient.
12,25 IL-10 is well known to inhibit T-cell-mediated IFN-g production. 26, 27 This might be important for the IL-10-mediated suppression of GvHD because IFN-g has been identified as a major mediator of GvHD in preclinical and clinical studies. 14, 15, 28 Our results here demonstrate that an increased number of T-1/IFN-g-producing recipient cells prior to transplantation sensitises the patient to develop severe GvHD after SCT. The pathomechanism behind this finding might be an inflammatory response initiated by IFN-g. For example, IFN-g is known to upregulate the expression of HLA and the adhesion molecule ICAM. 16, 17 In addition, it can activate macrophages and NK cells resulting in attraction of other immune competent cells into affected tissue. 29 However, there is still the question of how the detection of Tc-1 cells prior to transplantation could mediate the development of severe GvHD even in patients who received ATG during the conditioning regimen. The use of ATG in the treatment of aGvHD is still controversial. Depending on the type of ATG, the dose and the administration schedule, different effects on the progression/induction of remission of an aGvHD have been reported. [30] [31] [32] [33] Recently, Cragg et al 34 showed that ATG in addition to prednisone failed to improve GvHD when compared to a treatment regimen using prednisone alone. In addition, Remberger et al 35 demonstrated that the effect of ATG was best on the resolution of skin GvHD, while patients with liver or gut GvHD responded less well to ATG. Thus, tissue distribution of ATG might be variable. Nine out of 10 patients who presented with high Tc-1 cells prior to transplantation developed liver or gut GvHD. Thus, it might be conceivable that the Tc-1 cells detected prior to transplantation migrate to different tissues where these cells are not depleted by ATG. Later on, the Tc-1/IFN-g-producing cells might then stimulate antigen-presenting cells. In man, it is well known that IFN-g can activate antigen-presenting cells in vivo and in vitro. [36] [37] [38] In mice, it has been shown that host tissue antigen-presenting cells, which are not eliminated during conditioning, participate in the development of GvHD, especially across minor histocompatibility antigens. 39 Thus, in patients who present with high numbers of Tc-1 cells prior to transplantation, these preactivated lymphocytes might migrate into different patients' tissues leading to an activation of antigen-presenting cells, which then eventually leads to the development of GvHD.
Recently, we showed that IFN-g production by T cells is mediated by This cytokine is produced by several different cell types such as macrophages, dendritic cells or epithelial cells in response to bacterial or viral contact. 40 Thus, stimulation of macrophages with subsequent release of IL-12 might contribute to enhanced stimulation of T-1 cells, which in turn could then mediate the development of severe GvHD. In our study, we could not observe any correlation between IL-12 plasma levels and the development of aGvHD or the numbers of Tc-1 cells. However, detection of IL-12 in plasma samples might miss the relevant IL-12 compartment. Alternatively, the increased number of T-1 cells might absorb IL-12 and therefore an increased IL-12 production is not picked up by our analyses.
In conclusion, detection of T-1 cells prior to transplantation might help to identify patients at risk for the development of GvHD after allogeneic transplantation. Thus, based on these results, determination of Tc-1 cells prior to transplantation should be used for stratification of GvHD prophylaxis in multicentre trials including patients with one certain disease and one unique regimen with respect to conditioning regimen and GvHD prophylaxis.
